Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features

Ceravolo, Isabella; Barchetti, Giovanni; Biraschi, Francesco; Gerace, Carmela; Pampana, Enrico; Pingi, A; Stasolla, Alessandro

doi:10.1007/s11547-021-01401-4

Cited by 10 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been noted that the imaging results did not perfectly match the pathology findings. The presentations of T1WI and T2WI of GBMs using the current classification shared many similarities with the previous classification (30). Previous studies have found that contrast enhancement in mol-GBMs is a marker of aggressiveness (17).…”

Section: Discussionsupporting

confidence: 68%

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Guo

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionGlioblastoma (GBM), the most lethal primary brain malignancy, is divided into histological (hist-GBM) and molecular (mol-GBM) subtypes according to the 2021 World Health Organization classification of central nervous system tumors. This study aimed to characterize the clinical, radiological, molecular, and survival features of GBM under the current classification scheme and explore survival determinants.MethodsWe re-examined the genetic alterations of IDH-wildtype diffuse gliomas at our institute from 2011 to 2022, and enrolled GBMs for analysis after re-classification. Univariable and multivariable analyses were used to identify survival determinants.ResultsAmong 209 IDH-wildtype gliomas, 191 were GBMs, including 146 hist-GBMs (76%) and 45 mol-GBMs (24%). Patients with mol-GBMs were younger, less likely to develop preoperative motor dysfunction, and more likely to develop epilepsy than hist-GBMs. Mol-GBMs exhibited lower radiographic incidences of contrast enhancement and intratumoral necrosis. Common molecular features included copy-number changes in chromosomes 1, 7, 9, 10, and 19, as well as alterations in EGFR, TERT, CDKN2A/B, and PTEN, with distinct patterns observed between the two subtypes. The median overall survival (mOS) of GMB was 12.6 months. Mol-GBMs had a higher mOS than hist-GBMs, although not statistically significant (15.6 vs. 11.4 months, p=0.17). Older age, male sex, tumor involvement of deep brain structure or functional area, and genetic alterations in CDK4, CDK6, CIC, FGFR3, KMT5B, and MYB were predictors for a worse prognosis, while MGMT promoter methylation, maximal tumor resection, and treatment based on the Stupp protocol were predictive for better survival.ConclusionThe definition of GBM and its clinical, radiological, molecular, and prognostic characteristics have been altered under the current classification.

show abstract

Section: Discussionsupporting

confidence: 68%

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Guo

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…That said, if it is diagnosed early and treated appropriately, the survival period of gliomas can be considerably prolonged. [ 2 ] Therefore, it is imperative to establish early, stable, and reliable cancer screening methods to prolong the survival of GBM patients. [ 3 ] However, conventional imaging methods, such as magnetic resonance imaging (MRI) and X‐ray computed tomography (CT), are inaccurate in determining the size and location of brain tumors, while optical imaging is constrained by strong scattering of light in tissue and hence limited tissue penetration depth, even at near‐infrared (NIR) II wavelengths.…”

Section: Introductionmentioning

confidence: 99%

Deep Penetrating and Sensitive Targeted Magnetic Particle Imaging and Photothermal Therapy of Early‐Stage Glioblastoma Based on a Biomimetic Nanoplatform

et al. 2023

View full text Add to dashboard Cite

Early diagnosis can effectively improve the survival of glioblastoma multiforme (GBM). A specific imaging technique that is simultaneously deep penetrating and sensitive to small tissue changes is desired to identify GBM. Due to its excellent features in signal contrast, detection sensitivity, and none or little attenuation in tissue, magnetic particle imaging (MPI) possesses great potential in cancer diagnosis, especially when the imaging modality is equipped with specifically targeted nanoprobes. However, when gliomas are small, the blood–brain barrier (BBB) is complete and prevents nanoprobes from entering the brain, which negates the theranostic effect. This study proposes a biomimetic nanoplatform that assist the MPI tracers in breaking through the BBB and then demonstrate a targeted and sensitive diagnosis of GBM. Afterward, the photothermal therapy and immune regulation show an excellent therapeutic effect on the GBM. It is experimentally confirmed that the MPI signal does not decay with tissue depth and shows excellent sensitivity for thousands‐cells. Only small animals are conducted in this study due to the limitations of the current commercial MPI scanner, however, this research theoretically enables large animal and human studies, which encourages a promising pathway toward the noninvasive diagnosis of early‐stage GBM in clinics.

show abstract

“…Aggressive chemotherapy should be avoided because it is associated with significant morbidities. However, cytotoxic chemotherapy, non-cytotoxic systemic therapy and targeted therapy have been revealed as part of different treatment regimens [ 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ]. Cytotoxic chemotherapy is usually the first treatment option for rapidly growing and symptomatic unresectable or advanced diseases.…”

Section: Clinical Presentation and Treatmentmentioning

confidence: 99%

“…Recent progress regarding DT biology and molecular pathways has led to the development of promising novel biological agents. In any case, a multidisciplinary approach is required and is gradually employed, especially in intra-abdominal DTs [ 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ]. In addition, recent studies in the literature have shown that EADTs, following a correct surgical excision of the lesion with undamaged surgical margins, have a low rate of local recurrence and distant metastasis.…”

Section: Clinical Presentation and Treatmentmentioning

confidence: 99%

Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams

Simonetti

Bruno

Fusco

et al. 2022

JPM

View full text Add to dashboard Cite

Desmoid tumors (DTs), also known as desmoid fibromatosis or aggressive fibromatosis, are rare, locally invasive, non-metastatic soft tissue tumors. Although histological results represent the gold standard diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. Although histological analysis represents the gold standard for diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. DTs represent a challenge for the radiologist, being able to mimic different pathological conditions. A proper diagnosis is required to establish an adequate therapeutic approach. Multimodality imaging, including ultrasound (US), computed tomography (CT) and Magnetic Resonance Imaging (MRI), should be preferred. Different imaging techniques can also guide minimally invasive treatments and monitor their effectiveness. The purpose of this review is to describe the state-of-the-art multidisciplinary imaging of DTs; and its role in patient management.

show abstract

Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features

Cited by 10 publications

References 34 publications

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Deep Penetrating and Sensitive Targeted Magnetic Particle Imaging and Photothermal Therapy of Early‐Stage Glioblastoma Based on a Biomimetic Nanoplatform

Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams

Contact Info

Product

Resources

About